Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Altiratinib + Bevacizumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Altiratinib||DCC-2701||MET Inhibitor 55 Trk Receptor Inhibitor (Pan) 23||Altiratinib (DCC-2701) is an inhibitor of MET, VEGFR2, TIE2, and Trk that decreases endothelial cell survival and may inhibit cell proliferation and increase cell death in tumors expressing these factors (NCI Drug Dictionary).|
|Bevacizumab||Avastin||VEGF Antibody 10 VEGFR Inhibitor (Pan) 32||Avastin (bevacizumab) is a monoclonal antibody that binds VEGF and inhibits binding to VEGFR, potentially resulting in decreased tumor growth (PMID: 15136787). Avastin (bevacizumab) is FDA approved for use in colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical carcinoma, and ovarian cancer, and in combination with carboplatin and paclitaxel in epithelial ovarian, fallopian tube, or primary peritoneal cancer (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|